Navigation Links
Immunotech Completes Merger Acquisition
Date:3/30/2009

GLENDALE, Calif., March 30 /PRNewswire-FirstCall/ -- Immunotech Laboratories, Inc.(Pink Sheets: IMMB) has completed a reverse merger with a public shell company and has restructured its position through a 100 to 1 reverse split of stock. The company has issued 60 million authorized shares bringing the total number of issued and outstanding shares to 60,555,688 shares trading under NASDAQ OTC.PK Exchange ticker symbol IMMB.

Immunotech Laboratories, Inc. has indefinite licensing rights of the Irreversible Pepsin Fraction (IPF) peptide molecule for the specific treatment of the HIV/AIDS indication. IPF has demonstrated to have both fusion inhibitor and immunomodulator capabilities during in vitro studies with no viral resistance. This provides opportunities for patients that have already shown resistance to one or more antiretroviral therapies.

Immunotech Laboratories' core competency is in developing novel therapeutic molecules for the treatment of HIV/AIDS and a research pipeline with potential treatments for pre-natal and pediatric HIV/AIDS patients, subsequently developing a Preventive HIV Vaccine. The U.S. Patent office has granted full patent rights for IPF under patent number 7479538. Efforts are done to complete the pre-clinical studies in order to position the company's regulatory efforts in obtaining approval to initiate clinical phase I studies projected to start the 4th quarter of 2010. The company is in preparation to initiate efforts of acquiring fast track status designation from the FDA.

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable reg
'/>"/>

SOURCE Immunotech Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Eligard(R) six-month formulation successfully completes European approval procedure
2. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
3. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
4. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
5. GSI Securitization Completes Merger and Domicile Transfer
6. Medical Services International Inc. Completes Testing for European Union (EU) Application
7. Inverness Completes Acquisition of Cholestech
8. Billians HealthDATA Completes Comprehensive Long Term Care Database Update
9. Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants
10. Explorer completes the map ... for the bodys blueprint
11. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014. Kessler Foundation researchers have published a study ... the executive deficits found in individuals with multiple ... for executive deficits in multiple sclerosis? Evidence from ... ahead of print on August 18 by ... Victoria Leavitt, PhD, of the Manhattan Memory Center, ...
(Date:9/16/2014)... prospective study that compared patient-reported outcomes of a ... demonstrates that single fraction radiation therapy (SFRT) is ... (MFRT) when pain, function and quality of life ... the American Society for Radiation Oncology,s (ASTRO,s) 56th ... in patients, pain, function and degree of distress ...
(Date:9/16/2014)... presented at the ESMO 2014 Congress will be published ... to give you a first glimpse of what you ... the leading theme Precision Medicine in Cancer Care. , ... is now possible for an increasing number of cancers. ... a common goal --improved patient outcomes. This is the ...
(Date:9/16/2014)... 2014 The Pain Center of ... Ranking Arizona magazine, has selected Analance ™, ... , With TPC seeing hundreds of thousands of ... that was managed through “home grown” systems trying to ... clinical leadership teams. “Our current tools were not ...
(Date:9/16/2014)... September 16, 2014 Transparency Market Research, ... the global facial care market is expected to report ... report, titled ‘Facial Care Market (By Product Type - ... Cleansing Wipes, Serums and Masks and Others (fade creams, ... Growth, Trends and Forecast 2013 – 2019,’ is now ...
Breaking Medicine News(10 mins):Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 2Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 3Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 4Health News:ESMO 2014 Congress Preview 2Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 2Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 3Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 2Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 3
... Masimo (Nasdaq: MASI ),the inventor of Pulse ... today that the Pricing Committee of its Board of,Directors ... plan is designed to enhance the Board,s ability to ... company,that do not offer an adequate price to all ...
... AKL, MONTREAL, Nov. 9 /PRNewswire-FirstCall/ - Akela ... on developing therapies for the,inhalation and pain markets, ... accounting principles for the three and six,month period ... consolidated net loss for the third quarter of ...
... on what footwear works best , , FRIDAY, Nov. 9 (HealthDay ... flip-flops and flexible walking shoes than with other types ... to barefoot, the better for the knees, the study finds. ... not only affects your feet but can affect other joints ...
... Stryker Corporation,(NYSE: SYK ) announced today that ... revised from the previous announcement dated,November 1, 2007. ... Piper Jaffray Health Care Conference New York, ... presentation will be available,on Stryker,s website at http://www.stryker.com ...
... 9 Give an Hour, a,non-partisan, non-profit organization offering ... ones, announces there are 750,providers nationwide on its network., ... network 10 percent, or 40,000,people, of the approximately 400,000 ... average fee of $100 an hour, this would save,the ...
... only realistic way of preventing deaths and severe complications ... the disease, concludes research published ahead of print in ... healthcare workers and others likely to be at risk ... immunised in the UK. But vaccination programmes for children ...
Cached Medicine News:Health News:Masimo Corporation Adopts Stockholder Rights Plan 2Health News:Masimo Corporation Adopts Stockholder Rights Plan 3Health News:Akela Pharma reports results for third quarter of fiscal 2007 2Health News:Akela Pharma reports results for third quarter of fiscal 2007 3Health News:Akela Pharma reports results for third quarter of fiscal 2007 4Health News:Close to Barefoot Best for Arthritic Knees 2Health News:Close to Barefoot Best for Arthritic Knees 3Health News:Close to Barefoot Best for Arthritic Knees 4Health News:Stryker to Present at Investor Conference 2Health News:Non-Profit Calls on Mental Health Professionals to Honor Veterans Day by 'Giving an Hour' of Free Counseling to Returning Veterans 2Health News:Chicken pox vaccination should be introduced for children in the UK 2
(Date:9/16/2014)... , Sept. 16, 2014 On September 25 ... exhibition focusing on medical design and manufacturing - MEDTEC ... Shanghai World Expo Exhibition & Convention Center, bringing together ... and regions to showcase their latest medical-grade raw materials, ... only one week remaining for free visitor pre-registration to ...
(Date:9/16/2014)... , Sept. 16, 2014 The Lupus ... LLY ) today released results from UNVEIL: ... sheds light on the lupus journey and the challenges ... for lupus caregivers. The UNVEIL study, which involved over ... devastating impact lupus has on all aspects of life ...
(Date:9/16/2014)... Sept. 16, 2014  DNAtrix, Inc., experts in ... patient was treated with the company,s lead product, ... in a randomized, multicenter, open-label Phase Ib study ... in collaboration with leading neurosurgeons and neuro-oncologists in ... of our randomized Phase Ib study of DNX-2401 ...
Breaking Medicine Technology:MEDTEC China 2014: Seven Highlights Not to Miss! 2MEDTEC China 2014: Seven Highlights Not to Miss! 3MEDTEC China 2014: Seven Highlights Not to Miss! 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2
... 3 out of 4 Patients in Cohort 2 Demonstrate T-Cell ... Potential ... Biopharmaceuticals,Corporation (TSX: NVN) today announced interim immunological data from the,first ... its lead product,candidate, HspE7, in patients with cervical intraepithelial neoplasia, ...
... 25, Astellas Pharma US, Inc. and its co-development,partner ... COM) announced the first,pivotal Phase III study evaluating ... today in Circulation,the official journal of the American ... the Atrial arrhythmia Conversion Trial (ACT I),the primary ...
Cached Medicine Technology:Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 2Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 3Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 4Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 5Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 6Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm 2Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm 3Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm 4Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm 5
... Rapidlab 800 System is a fully automated, ... care whole blood parameters in addition to ... allows the basic blood gas model to ... electrolytes, metabolites and CO-oximetry in a single ...
Microcomputer controlled, preparative ultracentrifuge, with CFC-free refrigeration system. Available either internally cooled or with external water cooling. Quikset user interface, Softspin automati...
... Sorvall DiscoveryTMM150 SE Micro-ultra centrifuge continues ... volume sample processing, now with 1,048,000 x ... bucket rotor. DiscoveryTMM150SE processes sample sizes ... a small floor footprint, brushless direct drive, ...
... and environmental safety are the ... K Ultracentrifuge from Beckman Coulter. ... centrifugation technology, the LE-80 K ... provide advanced capability for your ...
Medicine Products: